Tumor News and Research

RSS

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.

From NanoString Technologies 11 Dec 2013

Discovery could lead to new way to combat cancer

One way to defeat an opponent is to cut off its supply lines. Tumors are no different. The supply lines for tumors are the blood vessels that ferry oxygen and nutrients to the cells. Restricting the blood vessels that feed tumor cells can shrink the tumor. A cross-institutional international team of scientists recently discovered a new, important step of the process that grows new blood vessels, a discovery that could lead to a new way to combat cancer.

11 Dec 2013

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.

10 Dec 2013

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.

10 Dec 2013

Researchers explain why anti-tumor activity of specific immune cells suppress during tumor growth

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth.

10 Dec 2013

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

Researchers in the Women's Cancer Program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes.

10 Dec 2013

Scientists devise method to measure forces in 3D tissues, living embryos

As embryonic tissue develops, cells push and pull on each other, and they must do so correctly for the tissue to develop properly. Now scientists at Harvard University have devised the first method to measure these forces in three-dimensional (3D) tissues and living embryos.

10 Dec 2013

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.

10 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Lymphotoxin is a cytokine, or intercellular messenger, and plays an important role in the immunological balance of the gastrointestinal tract. It regulates the immune system of the digestive tract, which is made up of immune cells, immunoglobulins (antibodies) as well as intestinal bacteria.

10 Dec 2013

UC Santa Barbara professor finds method for measuring cellular forces that shape tissues, organs

Like tiny construction workers, cells sculpt embryonic tissues and organs in 3D space. This task is complicated and requires constant communication between cells to coordinate their actions and generate the forces that will shape their environment into complex tissue morphologies.

10 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

9 Dec 2013

Increased inflammation in prostate may predict reduced risk for cancer

Doctors at the North Shore-LIJ Health System have discovered that increased inflammation in the prostate may predict reduced risk for prostate cancer. The findings are published online in CANCER.

9 Dec 2013

UC Davis experts call for updated prostate cancer treatment guidelines

With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to UC Davis prostate cancer experts.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Novel multi-kinase inhibitor shows early promise in NSCLC

Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer.

9 Dec 2013

Tumor News and Research

Navidea receives Fast Track designation for Lymphoseek injection

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

Discovery could lead to new way to combat cancer

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Researchers explain why anti-tumor activity of specific immune cells suppress during tumor growth

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

Scientists devise method to measure forces in 3D tissues, living embryos

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

UC Santa Barbara professor finds method for measuring cellular forces that shape tissues, organs

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Increased inflammation in prostate may predict reduced risk for cancer

UC Davis experts call for updated prostate cancer treatment guidelines

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Novel multi-kinase inhibitor shows early promise in NSCLC

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News